News
April 17, 2009
Researchers at McGill University in Montreal announced they will soon launch an international clinical trial to determine if latent tuberculosis can be treated successfully with a four-month treatment course of the TB drug rifampin rather than the standard nine-month treatment with the TB drug isoniazid.
April 17, 2009
The Areas Global TB Vaccine Foundation will soon begin a Phase II clinical trial of a new tuberculosis vaccine candidate that aims to improve on the existing BCG vaccine.
April 17, 2009
Although tuberculosis rates have declined in the U.S., drug-resistant strains of the disease are becoming increasingly prevalent in states with large immigrant populations.
April 17, 2009
An agreement between the Institute of Microbiology at the Chinese Academy of Sciences (Imcas) and the Global Alliance for TB Drug Development has been forged to develop new tuberculosis drugs from ingredients used in traditional Chinese medicine.
April 17, 2009
The Indian government plans to invest up to $2 billion, or Rs 10,000 crore, annually to develop more effective medicines for diseases such as
malaria and tuberculosis that hit thousands of Indians every year.
March 26, 2009
AdAg85A, a new tuberculosis vaccine, is set to begin a phase one clinical trial at McMaster University in Ontario.
March 26, 2009
Within a mouse model, the antitubercular compound BTZ043 shows significant bacterialcidal activity with no apparent side-effects.
March 26, 2009
The U.S. tuberculosis rate hit an all-time low in 2008.
March 26, 2009
Laboratory studies show that a combination of the drugs meropenem and clavulanate inhibited the growth of 13 separate strains of XDR-TB.
March 13, 2009
Conditions in Zimbabwe have hindered the ability of physicians to detect and treat tuberculosis, which could lead to a rise in unidentified cases of multi-drug and extensively drug-resistant TB, according to officials.
March 13, 2009
Fifty one new 1-(cyclopropyl/2,4-difluorophenyl/tert-butyl)-1,4-dihydro-8-methyl-6-nitro-4-oxo-7-(substituted secondary amino)quinoline-3-carboxylic acids were synthesized from 1,3-dichloro-2-methylbenzene and evaluated for in-vitro antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MTB)and multi-drug resistant Mycobacterium tuberculosis (MDR-TB).
March 13, 2009
A series of efavirenz Mannich bases were synthesized and evalutated for in vitro anti-HIV and antimycobacterial activities.
March 13, 2009
Combination treatment with two FDA-approved drugs shows promise in treating extensively drug-resistant tuberculosis (XDR-TB).
February 26, 2009
Researchers suggested that the ability of alginate to co-encapsulate multiple antitubercular drugs and offer a controlled release profile is likely to have a major impact in enhancing patient compliance for better management of tuberculosis.
Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
February 26, 2009
Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced the receipt of a Small Business Innovation Research (SBIR) Phase I Grant from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), to fund further preclinical development of the company's novel tuberculosis (TB) lead dipiperidine drug compound, SQ609.
February 26, 2009
An international team of researchers, led by Pooja Arora of the (Indian) National Institute of Immunology in New Delhi, has discovered a class of proteins called fatty acyl-AMP ligases (FAALs) that help TB in making lipids.
February 10, 2009
A new compound that destroys tuberculosis bacteria by attacking four metabolic pathways simultaneously could lead to the development of a single drug to treat TB.
February 10, 2009
This study explores the variability of biological responses from the perspective of sample purity and introduces the concept of purity-activity relationships (PARs) in natural product research.
February 10, 2009
This retrospective study reviews the incidence of XDR-TB in the United States from between 1993 through 2007.
February 10, 2009
12-Deoxy-11,12-dihydro-seco-hinokiol methyl ester (2), callicarpic acid B (5), and α-tocopherol trimer B (15) exhibit antitubercular activities (MICs ≤ 63.6 μM) against Mycobacterium tuberculosis H37Rv in vitro.
Displaying 81 through 100 of 836 items.
